# Night movers — Oct 12: AI headlines split the overnight board as Meta's Wonder models shined while chip names stu

_AI-generated trading idea · NEUTRAL · ACN, BMY, BSX, INTC, KO, LRCX, META, NIO, ORCL, VZ_

> Canonical page: https://commonquant.ai/research/for-you/night-movers-oct-12-ai-headlines-split-the-overnight-board-a--ef58fec4-31bb-5b97-8236-8691d32e774b

\#\# Session overview After-midnight gainers were led by META up 3.38%, ACN up 2.78%, VZ up 2.71%, BSX up 2.60%, and KO up 1.98%. Decliners were led by INTC down 3.20%, NIO down 3.07%, LRCX down 2.91%, ORCL down 2.84%, and BMY down 2.60%. \#\# Compared with previous session The prior night's gainers were led by AMT up 9.30%, VNET up 6.96%, MNSO up 5.84%, TME up 5.28%, and NIO up 4.99%, while decliners included DE down 4.85%, SBUX down 2.64%, CMCSA down 2.59%, INTC down 2.22%, and AON down 1.32%. This session's leaders were more modest, with META's 3.38% gain topping the board, and NIO and INTC flipped from the prior night's roster to lead the losers down 3.07% and 3.20% respectively. \#\# Gainers - \*\*META +3.38%\*\* — Meta rose 3.38% after releasing its new family of Wonder AI models, including Mu

## Idea

\#\# Session overview After-midnight gainers were led by META up 3.38%, ACN up 2.78%, VZ up 2.71%, BSX up 2.60%, and KO up 1.98%. Decliners were led by INTC down 3.20%, NIO down 3.07%, LRCX down 2.91%, ORCL down 2.84%, and BMY down 2.60%. \#\# Compared with previous session The prior night's gainers were led by AMT up 9.30%, VNET up 6.96%, MNSO up 5.84%, TME up 5.28%, and NIO up 4.99%, while decliners included DE down 4.85%, SBUX down 2.64%, CMCSA down 2.59%, INTC down 2.22%, and AON down 1.32%. This session's leaders were more modest, with META's 3.38% gain topping the board, and NIO and INTC flipped from the prior night's roster to lead the losers down 3.07% and 3.20% respectively. \#\# Gainers - \*\*META +3.38%\*\* — Meta rose 3.38% after releasing its new family of Wonder AI models, including Mu

## Advanced Analysis

### Verdict: wait for confirmation

Scope note: this rule set is not backtestable — the supplied BSX hourly history was too short to produce an evaluable evaluation window, so this is a research read rather than an active, validated signal. The strongest point for the idea is Boston Scientific's own book: revenue rose 4.6% sequentially to $5.4B, free cash flow swung from $171M to $1.28B, and 32 insiders were net open-market buyers of roughly $10.0M in the provisional filing for the period ending 2026-09-30 — the only net-buying name in this ten-stock basket. The strongest point against is quality of earnings: Q2 net income fell 32.4% sequentially to $905M and net margin compressed from 25.7% to 16.6%, and the mechanical entry itself is only half-live — the hourly stochastic (14) at 41.7 must fall to 30 or below and cross above the slower line at 24.4, and one condition (an hourly close below $0.00) cannot be met at any achievable price. With BSX already up 2.60% in the latest session, a strong follow-through would push the stochastic further from oversold and delay, not accelerate, the entry. The verdict would flip if the fiscal Q3 print (quarter ended 2026-09-30) shows net margin recovering toward the prior 25.7% level. Conviction breakdown: thesis support 60, trade readiness 40, risk quality 55, fundamentals trend 60.

#### Conviction score breakdown

Composite score computed by the server from the applicable evidence-tier dimensions.

| Measure | Value |
| --- | ---: |
| Thesis support | 60/100 |
| Trade readiness | 40/100 |
| Risk quality | 55/100 |
| Fundamentals trend | 60/100 |
| Score | 54/100 |
| Composite Score | 54/100 |
| Evidence Tier | not\_backtestable |

#### Decision scenarios

Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts.

| Measure | Value |
| --- | ---: |
| Evidence Tier | not\_backtestable |

### Trade now

The setup on the table is a \*\*long BSX\*\* entry built on four conditions, and today only two of them are in place. BSX's last hourly close is \*\*$42.92\*\*, sitting just below its 20-period Bollinger band at \*\*$43.01\*\* (condition met), but the 14-period stochastic reads \*\*41.7\*\* against a required reading at or below 30, and the faster stochastic line at \*\*24.4\*\* has not yet been crossed upward — both are still a meaningful distance from triggering. One additional entry condition requires the hourly close to be below $0.00; with BSX trading near $43, that condition cannot be met at any achievable price, which materially limits how this plan can play out as written. (Scope note: this rule set is not backtestable — the hourly data history supplied is too short to produce an evaluable evaluation window.)

If a position were taken, the risk framework is percent-based: a stop at \*\*-2.5%\*\* from entry (about \*\*$41.84\*\* at current prices) and a take-profit at \*\*+5.0%\*\* (about \*\*$45.06\*\*), an effective reward-to-risk of \*\*2.0:1\*\*. Secondary exits are an RSI (14) reading above 70 (currently \*\*44.6\*\*) and price touching the first daily resistance level, currently near \*\*$44.74\*\*.

Concretely, "wait" means: no action until the hourly stochastic (14) falls to 30 or below \*\*and\*\* crosses above the slower stochastic line. That needs roughly an 11-point drop in the stochastic from here. Meanwhile the exit side is far away — RSI at 44.6 would need to rise more than 25 points to hit the 70 exit — so nothing on the exit side constrains today's decision.

#### ACN price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | ACN |
| Timeframe | 1h |

#### BMY price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | BMY |
| Timeframe | 1h |

#### BSX price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | BSX |
| Timeframe | 1h |

### Fundamentals behind the session's movers are real, not just tape

One scope note up front: this idea's rules could not be evaluated over the supplied windows (the strategy's BSX hourly data lacked the required warm-up candles in both the 12-month and 1-month windows), so this is a research read on the underlying names rather than an active, validated signal.

The session's gainers line up with genuinely improving fundamentals. Meta, up 3.38% after its Wonder AI model release per the MarketWatch report, posted Q2 revenue of $60.8B, up 8.0% from the prior quarter, with a 38.0% net margin — and its Q4 fiscal 2025 snapshot shows revenue growth of 23.8% year over year with a 41.3% operating margin, placing it in the top 3% of communication-services peers. Accenture, up 2.78%, grew Q3 revenue 3.7% sequentially to $18.7B with net income jumping 28.2% to $2.34B and operating margin expanding 3.1 points to 17.0%. Verizon's 2.71% bounce came with a 30.7% sequential operating cash flow increase to $10.4B.

Boston Scientific, up 2.60%, is the strongest fundamental outlier in the group: revenue rose 4.6% sequentially to $5.4B, free cash flow swung from $171M to $1.28B, and the fiscal 2025 snapshot shows 15.8% revenue growth with an operating margin in the top 13% of health-care peers. Coca-Cola, up 1.98%, grew revenue 5.5% with net margin expanding to 31.5% and operating margin at 35.0% — top-decile consumer staples economics.

On the declining side, Bristol Myers' 2.60% dip looks like it may be fighting its own numbers: Q2 revenue rose 12.9% to $12.97B, net income rose 23.9% to $3.32B, free cash flow quadrupled to $3.09B, and debt-to-equity fell from 2.22 to 1.93 — all while a late-stage lung-disease trial succeeded at a lower dose per Reuters. Whether the market gives that trial read its due is the unresolved question.

The idea's neutral framing is well-calibrated: the leaders carry mostly clean books (Accenture holds $11.5B in cash against roughly $34.2B in liabilities with a 1.42 current ratio), while the decliners include the names with genuine fundamental deterioration — Intel, down 3.20%, swung to an $11.0B quarterly net loss with a negative 68.4% net margin, and Oracle, down 2.84%, is burning cash (negative $5.4B free cash flow in its latest quarter) despite 20.6% annual revenue growth.

#### NIO Revenue

Revenue trend from CommonQuant fundamentals/XBRL data; first value is near zero; use the latest value directly.

| Measure | Value |
| --- | ---: |
| 2016-12-31 | $0 |
| 2017-12-31 | $0 |
| 2018-12-31 | $4951171000 |
| 2019-12-31 | $1123978000 |
| 2020-12-31 | $2491637000 |
| 2021-12-31 | $5670593000 |
| 2022-12-31 | $7143270000 |
| 2023-12-31 | $7833622000 |
| 2024-12-31 | $9005187000 |
| 2025-12-31 | $12510547000 |
| Latest Value | $12510547000 |
| Ticker | NIO |
| Timeframe | reported periods |

#### BSX Operating margin

Operating margin trend from CommonQuant fundamentals/XBRL data; +7919.9% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2007-12-31 | \-0.0016752423118343903% |
| 2008-06-30 | \0.14970355731225296% |
| 2008-09-30 | \0.014155712841253791% |
| 2008-12-31 | \-0.18695652173913044% |
| 2009-03-31 | \0.005472636815920398% |
| 2009-06-30 | \0.1325940212150434% |
| 2009-09-30 | \0.025185185185185185% |
| 2009-12-31 | \-0.10918417195896436% |
| 2009-12-31 | \-0.592111592111592% |
| 2010-03-31 | \-0.7581632653061224% |
| 2010-06-30 | \0.11981327800829876% |
| 2010-09-30 | \0.13100208768267224% |
| Latest Value | \0.13100208768267224% |
| Change Pct | \7919.888905457799% |
| Ticker | BSX |
| Timeframe | reported periods |

#### ACN sector percentile check

Ranks ACN against 833 companies in its sector using CommonQuant fundamentals.

| Measure | Value |
| --- | ---: |
| Free cash flow | \98.91956782713083th percentile |
| Operating margin | \78.53170189098999th percentile |
| Gross margin | \26.956521739130434th percentile |
| Return on equity | \56.877323420074354th percentile |
| Ticker | ACN |
| Sector | Information Technology |
| Peer Count | 833 |

### What could break the session's rotation

The most serious warning in the group comes from the insiders, not the tape. Net open-market selling was registered for the period ending September 30 across most of the roster: KO insiders sold a net $81.1M, META insiders a net $57.4M, ORCL insiders a net $45.0M, LRCX insiders a net $58.3M, and INTC insiders a net $6.5M. Those sales are disclosed as of the September 30 filing period — not current as of the October 14 retrieval — but the breadth of selling among exactly the stocks the market bid up overnight (META, KO) is a genuine overhang on the rotation.

Oracle is the weakest fundamental book among the decliners despite its premium multiple narrative: free cash flow was negative $18.7B in fiscal Q4 and deepened to negative $5.4B in the latest quarter as capex ran $16.5B in a single quarter. Its 20.6% revenue growth is real, but it is being financed, not funded — and interest expense of $1.44B per quarter reflects it. If the AI capital crunch the CNBC piece describes (Intel and Broadcom CEOs warning the capital crunch could become AI's biggest bottleneck) tightens, Oracle's cash burn becomes the story.

Intel itself is a turnaround bet on air: a net loss of $11.0B on $16.1B revenue in the latest quarter, revenue down 4.1% year over year in fiscal 2025, debt-to-equity rising from 0.40 to 0.58 in a single quarter, and zero trailing dividends. Boston Scientific also shows fragility beneath its headline: Q2 net income fell 32.4% and net margin compressed 9.1 points to 16.6%, even as revenue grew — quality of earnings, not just quantity, matters here.

Dividend postures expose who has room to disappoint. Accenture raised its payout to $4.97 trailing annually (11.9% growth) and Verizon and Coca-Cola pay steadily, but Meta's annual dividend of $1.575 in 2026 marks only about 1.2% growth and its free cash flow collapsed 86.8% sequentially to $1.7B on $21.4B of capex — the buyback-and-dividend story is being squeezed by AI spending. Lam Research, down 2.91%, carries the best fundamentals of the decliners (33.9% net margin, 30.0% revenue growth, top 2% operating margin in tech), so its slide reads as positioning rather than deterioration — which cuts both ways: if semis roll over again, LRCX's insider selling and cyclicality bite hardest.

Finally, NIO's 3.07% drop follows an equity count that keeps climbing: shares outstanding rose 18.3% year over year to 2.47B, ROE sits at roughly negative 359%, and it remains in the bottom 2% of consumer-discretionary free cash flow. As a watch-list idea with no validated entries, the reader should treat the session's moves as hypothesis, not signal.

#### ORCL Debt to equity

Debt to equity trend from CommonQuant fundamentals/XBRL data; +9680.1% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2015-05-31 | \0.8622156463843166 ratio |
| 2016-05-31 | \0.9273826894203724 ratio |
| 2017-05-31 | \1.0751763832157446 ratio |
| 2018-05-31 | \1.307232812904339 ratio |
| 2019-05-31 | \2.5782419095708056 ratio |
| 2020-05-31 | \5.929849262878913 ratio |
| 2021-05-31 | \16.083428789614356 ratio |
| 2023-05-31 | \84.32525629077354 ratio |
| Latest Value | \84.32525629077354 ratio |
| Change Pct | \9680.065653458012 ratio |
| Ticker | ORCL |
| Timeframe | reported periods |

#### NIO Return on equity

Return on equity trend from CommonQuant fundamentals/XBRL data; -646.8% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2016-12-31 | \0.6570524670867847% |
| 2017-12-31 | \0.4327445906861526% |
| 2018-12-31 | \-1.4098173464222314% |
| 2019-12-31 | \1.7930475834738653% |
| 2020-12-31 | \-0.19522715515564368% |
| 2021-12-31 | \-0.11572950739010314% |
| 2022-12-31 | \-0.6048684620028152% |
| 2023-12-31 | \-0.8110689192190013% |
| 2024-12-31 | \-3.7542551603835217% |
| 2025-12-31 | \-3.59243604939517% |
| Latest Value | \-3.59243604939517% |
| Change Pct | \-646.7502565393571% |
| Ticker | NIO |
| Timeframe | reported periods |

### Company context

\#\#\# ACN \*\*Ownership and insiders.\*\* For the period ending 2026-09-30, 61 reporting holders were counted holding 2247503 reported shares. Insider filings indicate net open-market selling, netting US$-1872639.73. Coverage: Provisional. \*\*Management.\*\* Ms. Julie T. Spellman Sweet J.D. is identified as chief executive. Ms. Julie T. Spellman Sweet J.D. is listed as CEO & Chairman, with reported total pay of US$6.8M for fiscal 2025. Source: \[Yahoo Finance quoteSummary\](https://finance.yahoo.com/quote/ACN/profile), retrieved 2026-10-14T13:52:58.57+00:00. \*\*Dividends.\*\* Trailing twelve-month distributions total USD 4.97 per share; the latest observed ex-date was 2026-10-13 at USD 1.71 per share. The latest annual comparison is +11.9%. Source: \[Yahoo Finance corporate actions\](https://finance.yahoo.com/quote/ACN/history?filter=div), retrieved 2026-10-14T13:52:58.57+00:00. \*\*Fundamental changes.\*\* Latest reported comparisons: - Free cash flow: USD 3.6B for Q3 ending 2026-05-31 versus USD 3.7B for Q2 ending 2026-02-28 (-1.9%) · quarter over quarter - Gross margin: 32.7% for Q3 ending 2026-05-31 versus 30.2% for Q2 ending 2026-02-28 (+2.5 percentage points) · quarter over quarter - Net Income: USD 2.3B for Q3 ending 2026-05-31 versus USD 1.8B for Q2 ending 2026-02-28 (+28.1%) · quarter over quarter - Net margin: 12.4% for Q3 ending 2026-05-31 versus 10.1% for Q2 ending 2026-02-28 (+2.4 percentage points) · quarter over quarter - Operating Cash Flow: USD 3.8B for Q3 ending 2026-05-31 versus USD 3.8B for Q2 ending 2026-02-28 (-0.8%) · quarter over quarter - Operating margin: 16.9% for Q3 ending 2026-05-31 versus 13.8% for Q2 ending 2026-02-28 (+3.1 percentage points) · quarter over quarter - Revenue: USD 18.7B for Q3 ending 2026-05-31 versus USD 18.0B for Q2 ending 2026-02-28 (+3.7%) · quarter over quarter - Return on equity: 7.3% for Q3 ending 2026-05-31 versus 5.8% for Q2 ending 2026-02-28 (+1.5 percentage points) · quarter over quarter Source: Reported company financial data. Comparisons use consecutive reported periods at the same cadence and compatible units. Relative percentage changes require a positive baseline; rate changes are expressed in percentage points. \*\*Unavailable comparisons.\*\* - Debt to equity: The latest period's value is unavailable. - Shares Outstanding: The latest period's value is unavailable. \#\#\# BMY \*\*Ownership and insiders.\*\* For the period ending 2026-09-30, 90 reporting holders were counted holding 4306793 reported shares. Insider filings indicate net open-market selling, netting US$-437247.93. Coverage: Provisional. \*\*Management.\*\* Dr. Christopher S. Boerner Ph.D. is identified as chief executive. Dr. Christopher S. Boerner Ph.D. is listed as CEO & Chairman, with reported total pay of US$5.8M for fiscal 2025. Source: \[Yahoo Finance quoteSummary\](https://finance.yahoo.com/quote/BMY/profile), retrieved 2026-10-14T13:52:58.57+00:00. \*\*Dividends.\*\* Trailing twelve-month distributions total USD 2.52 per share; the latest observed ex-date was 2026-10-02 at USD 0.63 per share. The latest annual comparison is +1.6%. Source: \[Yahoo Finance corporate actions\](https://finance.yahoo.com/quote/BMY/history?filter=div), retrieved 2026-10-14T13:52:58.57+00:00. \*\*Fundamental changes.\*\* Latest reported comparisons: - Debt to equity: 1.93x for Q2 ending 2026-06-30 versus 2.22x for Q1 ending 2026-03-31 (-12.8%) · quarter over quarter - Free cash flow: USD 3.1B for Q2 ending 2026-06-30 versus USD 757.0M for Q1 ending 2026-03-31 (+307.9%) · quarter over quarter - Gross margin: 71.2% for Q2 ending 2026-06-30 versus 70.2% for Q1 ending 2026-03-31 (+1.1 percentage points) · quarter over quarter - Net Income: USD 3.3B for Q2…

### Scores

- **Conviction score breakdown:** 54
- **Thesis support:** 60
- **Trade readiness:** 40
- **Risk quality:** 55
- **Fundamentals trend:** 60

### Watch items

- **BSX — Stochastic (14), hourly**
- **BSX — Stochastic (14) vs slower stochastic line, hourly**
- **BSX — Price vs 20-period Bollinger band, hourly**
- **BSX — RSI (14), hourly**
- **BSX — Insider net open-market activity**
- **BSX — Fiscal Q3 earnings report**

## Key details

- Symbols: ACN, BMY, BSX, INTC, KO, LRCX, META, NIO, ORCL, VZ
- Timeframes: 1h
- Tags: \#canonical-demand, \#cluster-version:1, \#direction:neutral, \#entity-kind:instrument, \#entity:ACN, \#entity:BMY, \#entity:BSX, \#entity:INTC, \#entity:KO, \#entity:LRCX, \#entity:META, \#entity:NIO, \#entity:ORCL, \#entity:VZ, \#horizon:short\_term, \#intent:research, \#symbol:ACN, \#symbol:BMY, \#symbol:BSX, \#symbol:INTC, \#symbol:KO, \#symbol:LRCX, \#symbol:META, \#symbol:NIO, \#symbol:ORCL, \#symbol:VZ

## Community

- Upvotes: 0
- Views: 3
- Copies: 0
- Cosigns: 0

## News sources

- [Meta is back on the AI leaderboard with its new family of Wonder models](https://www.marketwatch.com/story/meta-is-back-on-the-ai-leaderboard-with-its-new-family-of-wonder-models-a704b6cc?mod=mw_rss_topstories) — MarketWatch Top Stories
- [Intel, Broadcom CEOs warn capital crunch could become AI's biggest bottleneck](https://www.cnbc.com/2026/10/12/intel-broadcom-ceos-warn-capital-crunch-could-become-ai-bottleneck.html) — CNBC Top News
- [Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial - Reuters](https://news.google.com/rss/articles/CBMi0gFBVV95cUxPeGJ3Z05LT3J5U1dNMmFNMWlGakpSek1jOEJUR2VsZ3hmS1lPb0NOQ3hmQWduNjltY3lkcE1IazJObkxaUHhfZ0Uxc1N6Qzh5bHdzblE0WFNmeEItazdqRjB5M2VkOTRYX3p6T1FVb3huVW51eGQ0cEdYeVNpajJKbWNSVm9BWWtfMVNoUXI0YW1kVUdIZko5VC11SjlHZEZqNnptTFJRWFJ0LU5JYXRTMlZxWVl2M1dySFVIckxkRjN6NmJKNERIc1E3VGEyR09ianc?oc=5) — Reuters

## Related

- [ACN trade ideas](https://commonquant.ai/markets/acn)
- [BMY trade ideas](https://commonquant.ai/markets/bmy)
- [BSX trade ideas](https://commonquant.ai/markets/bsx)
- [INTC trade ideas](https://commonquant.ai/markets/intc)
- [KO trade ideas](https://commonquant.ai/markets/ko)
- [LRCX trade ideas](https://commonquant.ai/markets/lrcx)
- [META trade ideas](https://commonquant.ai/markets/meta)
- [NIO trade ideas](https://commonquant.ai/markets/nio)
- [ORCL trade ideas](https://commonquant.ai/markets/orcl)
- [VZ trade ideas](https://commonquant.ai/markets/vz)
- [Latest market news](https://commonquant.ai/news)

## About CommonQuant Research

Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (over a timeframe-dependent historical window with walk-forward tuning) and stress-tested before they can go live, then monitored against the news hourly while they run.